Probiotic Saccharomyces boulardii CNCM I-745: from research to clinical practice
DOI:
https://doi.org/10.61997/bjm.v6i2.144Keywords:
Saccharomyces boulardii CNCM I-745, probiotics, pharmacodynamics, pharmacokineticsAbstract
An update on the unique yeast with probiotic action Saccharomyces boulardii CNCM I-745 is presented from research to clinical
practice, following the principles of evidence-based medicine due to the results achieved in clinical trials and meta-analyzes. The
characteristics of its pharmacodynamics and pharmacokinetics are reviewed. Its mechanisms of action are detailed based on research carried out in vitro, in animals and humans. The indications for its clinical use in different intestinal diseases with special reference to acute infectious gastroenteritis and its prevention, antibiotic associated diarrhea, recurrent diarrhea by Clostridium difficile and its prevention and other intestinal disorders such as dysbiosis, irritable colon and traveler's diarrhea are shown. Reference is made to its safety and adverse effects. The advantages of the only probiotic yeast regarding bacterial probiotics are established.
Downloads
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
BJM protects Copyright at all times. However, it gives up part of the rights by displaying a Creative Commons License 4.0 (cc-by-nc), which allows the use of the work to share (copy and redistribute the material in any support or format) and adapt (transform and built from the material) as long as exclusive mention of the publication in the journal as the primary source is made. Under no circumstances, the work can be commercialized.





